Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results of two phase II trials and prognostic factor analysis for survival

被引：0
|
作者：
Rosenberg, J. E.
Motzer, R. J.
Michaelson, M. D.
Redman, B. G.
Hudes, G. R.
Bukowski, R. M.
George, D. J.
Kim, S. T.
Baum, C. M.
Wilding, G.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[6] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA
[7] Duke Univ, Med Ctr, Durham, NC USA
[8] Pfizer Inc, San Diego, CA USA
[9] Univ Wisconsin, Madison, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5095
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results from a phase I/II study
    Redman, B. G.
    Hudes, G. R.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] External validation of a sunitinib prognostic nomogram in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Yu, Changhong
    Kattan, Michael W.
    Hutson, Thomas E.
    Hudes, Gary R.
    Yuan, Jinyu
    Valota, Olga
    Motzer, Robert John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] A phase II study of intermittent sunitinib in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC).
    Wood, Laura S.
    Dreicer, Robert
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ali, Khaled B.
    Haddad, Housam
    Shah, Shetal N.
    Elson, Paul
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): Updated results
    Srinivas, S.
    Roigas, J.
    Gillessen, S.
    Harmenberg, U.
    De Mulder, P. H.
    Fountzilas, G.
    Vogelzang, N.
    Peschel, C.
    Flodgren, P.
    Escudier, B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers
    George, D. J.
    Michaelson, M. D.
    Rosenberg, J. E.
    Bukowski, R. M.
    Sosman, J. A.
    Stadler, W. M.
    Margolin, K.
    Hutson, T. E.
    Rini, B. I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Skin toxicity of sunitinib: Prospective analysis in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Billemont, B.
    Barete, S.
    Meric, J. B.
    Moguelet, P.
    Frances, C.
    Chosidow, O.
    Goldwasser, F.
    Rixe, O.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Patel, P. H.
    Kondagunta, G. V.
    Redman, B. G.
    Hudes, G. R.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] A phase II study of intermittent sunitinib (S) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC)
    Rini, Brian I.
    Wood, Laura S.
    Elson, Paul
    Zhu, Hui
    Chittoria, Namita
    Mittal, Kriti
    Dreicer, Robert
    Gilligan, Timothy D.
    Shah, Shetal N.
    Garcia, Jorge A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma
    Tomita, Yoshihiko
    Shinohara, Nobuo
    Yuasa, Takeshi
    Fujimoto, Hiroyuki
    Niwakawa, Masashi
    Mugiya, Soichi
    Miki, Tsuneharu
    Uemura, Hirotsugu
    Nonomura, Norio
    Takahashi, Masayuki
    Hasegawa, Yoshihiro
    Agata, Naoki
    Houk, Brett
    Naito, Seiji
    Akaza, Hideyuki
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (12) : 1166 - 1172
  • [10] Outcomes of sunitinib therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) with poor risk features
    Barroso-Sousa, Romualdo
    Munhoz, Rodrigo Ramella
    Fonseca, Leonardo Gomes
    de Sousa Fede, Angelo Bezerra
    Marques Linck, Rudinei Diogo
    Venchiarutti Moniz, Camila Motta
    Mak, Milena Perez
    Souza, Ciro Eduardo
    Hoff, Paulo M.
    Dzik, Carlos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345